NYSE:VOR Vor Biopharma (VOR) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free VOR Stock Alerts $1.74 -0.14 (-7.45%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.73▼$1.8750-Day Range$1.68▼$2.3752-Week Range$1.62▼$5.70Volume286,829 shsAverage Volume293,442 shsMarket Capitalization$118.70 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Vor Biopharma alerts: Email Address Vor Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside675.9% Upside$13.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.34) to ($1.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.49 out of 5 starsMedical Sector271st out of 907 stocks 4.5 Analyst's Opinion Consensus RatingVor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVor Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VOR. Previous Next 0.0 Dividend Strength Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VOR. Previous Next 2.4 News and Social Media Coverage News SentimentVor Biopharma has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vor Biopharma this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat Follows6 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.40% of the stock of Vor Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vor Biopharma are expected to grow in the coming year, from ($1.34) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vor Biopharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vor Biopharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Vor Biopharma Stock (NYSE:VOR)Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More VOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VOR Stock News HeadlinesApril 24, 2024 | americanbankingnews.comVor Biopharma (NYSE:VOR) Receives Outperform Rating from WedbushApril 16, 2024 | americanbankingnews.comVor Biopharma (NYSE:VOR) Trading Down 5.3%April 25, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialApril 1, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMarch 29, 2024 | finance.yahoo.comHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn SituationMarch 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessMarch 26, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)April 25, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...March 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)March 22, 2024 | finanznachrichten.deVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 21, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)March 20, 2024 | benzinga.comVor Biopharma: Q4 Earnings InsightsMarch 20, 2024 | finance.yahoo.comVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 20, 2024 | globenewswire.comVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 19, 2024 | msn.comIntellia Therapeutics doses first patient in pivotal in vivo CRISPR trialMarch 16, 2024 | finance.yahoo.comVOR Apr 2024 5.000 callMarch 5, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesFebruary 17, 2024 | finance.yahoo.comInstitutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the companyFebruary 15, 2024 | finance.yahoo.com2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)February 7, 2024 | finance.yahoo.comVor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finanznachrichten.dePersonnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are welcomed as new members of the Executive BoardJanuary 31, 2024 | msn.comVaxart spikes as B. Riley upgrades at long last after BARDA fundingJanuary 18, 2024 | finanznachrichten.deVor Biopharma: Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate UpdateJanuary 17, 2024 | finance.yahoo.comVor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate UpdateJanuary 9, 2024 | markets.businessinsider.comBuy Rating Justified by CRISPR Therapeutics’ Strong Pipeline and Market PotentialSee More Headlines Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry N/A Sub-IndustryN/A Current SymbolNYSE:VOR CUSIPN/A CIK1817229 Webwww.vorbiopharma.com Phone617-655-6580FaxN/AEmployees168Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$17.50 Low Stock Price Target$11.00 Potential Upside/Downside+675.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares68,220,000Free Float54,300,000Market Cap$118.70 million OptionableNot Optionable Beta-0.36 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Robert Ang M.B.A. (Age 49)M.D., MBBS, President, CEO & Director Comp: $943.91kMr. Samir Vattompadam M.S.Senior Vice President of Portfolio Strategy & Program ManagementMr. David Phillips M.B.A.Senior VP & Head of QualityKey CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMFitLife BrandsNASDAQ:FTLFOmega TherapeuticsNASDAQ:OMGAGenetronNASDAQ:GTHOutset MedicalNASDAQ:OMView All Competitors VOR Stock Analysis - Frequently Asked Questions Should I buy or sell Vor Biopharma stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VOR shares. View VOR analyst ratings or view top-rated stocks. What is Vor Biopharma's stock price target for 2024? 5 Wall Street research analysts have issued 12-month target prices for Vor Biopharma's shares. Their VOR share price targets range from $11.00 to $17.50. On average, they anticipate the company's stock price to reach $13.50 in the next year. This suggests a possible upside of 675.9% from the stock's current price. View analysts price targets for VOR or view top-rated stocks among Wall Street analysts. How have VOR shares performed in 2024? Vor Biopharma's stock was trading at $2.25 at the start of the year. Since then, VOR stock has decreased by 22.7% and is now trading at $1.74. View the best growth stocks for 2024 here. When is Vor Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VOR earnings forecast. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NYSE:VOR) issued its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.10. What ETFs hold Vor Biopharma's stock? ETFs with the largest weight of Vor Biopharma (NYSE:VOR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VOR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
